Multicenter Registry of Very Early and Late Clinical Outcomes to Everolimus-eluting Cobalt-Chromium Stent In Patients With ST Elevation Myocardial Infarction
NCT ID: NCT02792920
Last Updated: 2016-06-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
400 participants
INTERVENTIONAL
2016-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Also, OCT sub-analysis will be conducted
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
National Multicenter Cohort Registry Study of Rapid rEcurrences of Coronary Unexplained In-stent Restenosis
NCT05437965
Determination of the Duration of the Dual Antiplatelet Therapy by the Degree of the Coverage of The Struts on Optical Coherence Tomography From the Randomized Comparison Between Everolimus-eluting Stents Versus Biolimus A9-eluting Stents
NCT03873012
Healing Response to Everolimus-eluting Stent Implantation; Serial Assessment With opticaL Coherence Tomography
NCT01689688
Multicentre Registry of CCTA, IVUS and OCT
NCT04066062
Does Co-registration of OCT and Angiography Reduce Geographic Miss of Stent Implantation?
NCT02671123
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
CoCr-EES
CoCr-EES
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CoCr-EES
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Patients with no history of PCI in the target vessel
3. Patients who are 20 or older at the time of informed consent
4. Patients who provided written informed consent by himself/herself
5. Patients who are judged by their treating physician to be able to undergo PCI with CoCr-EES
6. Patients for whom thrombus aspiration prior to CoCr-EES implantation can be recommended
8. Patients were obtained finally revascularization of TIMI 3 by visual observation in the target vessel
9. Patients who are able to treat with CoCr-EES the diameter 2.5mm or more and 3.5mm or less and the length of 8mm or more and 28mm or less.
Exclusion Criteria
2. Patients presenting with cardiogenic shock
3. Patients for whom 12-month and 36-month CAG and clinical follow up is considered difficult (patient's residence should also be taken into account)
4. Patients with responsible lesion in left main trunk
5. Patients with renal insufficiency or with chronic renal failure with serum creatinine level of 2.0mg/dL or higher at visit
6. Patients on hemodialysis
7. Patients with a known history of adverse drug reactions to aspirin, or clopidogrel or prasugrel (This may not apply if safety of ticlopidine is confirmed as an alternative drug.)
8. Patients who are below the age of 20
9. Women who were positive in pregnancy test or wish to become pregnant during study duration
10. Patients who newly developed AMI attributable to the prior stented site
11. Patients with a known history of allergy to drug, polymer, metal, and other materials used in CoCr-EES
12. Patients diagnosed with hepatic insufficiency
13. Patients with target lesion in saphenous vein graft
14. Patients with active malignant tumor
20 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hyogo Brain and Heart Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hyogo Brain and Heart Center
Himeji, Hyogo,, , Japan
Higashi Takarazuka Sato Hospital
Takarazuka, Hyogo, , Japan
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Yoshinori Yasaka, M.D.
Role: primary
Satoru Otsuji, M.D.
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
XIENCE STEMI Registry
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.